Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...

As we celebrate ten years of bringing you the latest news, here's a look back to some of the first stories to make the ...

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Art Garfunkel, 83, talks exclusively with PEOPLE about taking a step back from his career to prioritize his health amid his ...

Marisa Garshick, MD, a board-certified dermatologist and clinical assistant professor, discusses resources and tools that can ...

A dry scalp is a common condition that occurs when the skin on the scalp lacks moisture, leading to itching, irritation, and ...

Psoriasis doesn’t prevent you from having a cosmetic procedure, but there are safety and timing concerns to consider. Learn ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Post-hoc analyses of the EFFISAYIL 2 trial revealed improvements in Psoriasis Symptom Scale (PSS), Pain Visual Analog Scale ...